RSS Feeds
Emerging Resistance to Fluoroquinolones in Staphylococci: An Alert
- Michele Trucksis, PhD, MD;
- David C. Hooper, MD; and
- John S. Wolfson, MD, PhD
Excerpt
The fluoroquinolones are orally administered antimicrobial agents introduced in the mid-1980s. Although they are particularly effective for treating gram-negative bacillary infections, some agents, including ciprofloxacin, ofloxacin, and pefloxacin, are also active against gram-positive organisms. These agents have shown promise as alternatives to parenteral vancomycin for treating infections with methicillin-resistant Staphylococcus aureus. With fluoroquinolone use, however, therapeutic failures associated with isolation of fluoroquinolone-resistant strains of staphylococci are being increasingly documented. We discuss the use of fluoroquinolones as therapeutic agents for staphylococcal infections, problems with bacterial resistance, and approaches to suppression of resistance.
Staphylococci have long been important causes of both community-
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
Grant Support: By grants from the Public Health Service and National Institutes of Health RO1 AI23988 and Training Grant AI07061.
-
Requests for Reprints: John S. Wolfson, MD, PhD: Infectious Disease Unit, Massachusetts General Hospital, 32 Fruit Street, Boston, MA 02114-2696.
